Cerevel Therapeutics Inc... (CERE)
NASDAQ: CERE
· Real-Time Price · USD
44.96
0.33 (0.74%)
At close: Jul 31, 2024, 10:00 PM
Cerevel Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 8.25M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 1.54M | 1.5M | 1.45M | 1.35M | 1.32M | 1.29M | 1.27M | 1.22M | 1.12M | 1.64M | 980K | 601K | 63K |
Gross Profit | -1.54M | 6.74M | -1.45M | -1.35M | -1.32M | -1.29M | -1.27M | -1.22M | -1.12M | -1.64M | -980K | -601K | -63K |
Operating Income | -142.66M | -139.56M | -111.31M | -96.84M | -99.55M | -107.25M | -95.06M | -93.01M | -72.53M | -64.49M | -54.53M | -50.51M | -50.57M |
Interest Income | 14.46M | 15.08M | 9.89M | 9.82M | 6.44M | 5.95M | 3.99M | 667K | 295K | 119K | 13K | 10K | 15K |
Pretax Income | -131.77M | -132.47M | -96.24M | -99.43M | -104.2M | -92.65M | -99.94M | -90.47M | -68.29M | -59.05M | -62.06M | -53.24M | -50.98M |
Net Income | -131.91M | -132.66M | -96.36M | -99.53M | -104.29M | -92.81M | -104.81M | -90.47M | -64.06M | -59.05M | -62.06M | -53.24M | -50.98M |
Selling & General & Admin | 36.23M | 40.93M | 26.05M | 22.76M | 21.37M | 25.93M | 23.68M | 20.47M | 17.51M | 16.65M | 14.37M | 13.22M | 14.01M |
Research & Development | 106.42M | 97.13M | 85.25M | 74.08M | 78.18M | 81.31M | 71.39M | 72.54M | 55.02M | 47.84M | 40.16M | 37.29M | 36.56M |
Other Expenses | -921K | n/a | 7.82M | -9.77M | -11.09M | 8.65M | 21K | 8K | 1K | 5.32M | -7.54M | -2.74M | -425K |
Operating Expenses | 142.66M | 138.06M | 111.31M | 96.84M | 99.55M | 107.25M | 95.06M | 93.01M | 72.53M | 64.49M | 54.53M | 50.51M | 50.57M |
Interest Expense | 2.65M | 2.65M | 2.64M | 2.64M | 6.44M | 5.95M | 1.29M | n/a | 295K | 119K | 13K | 10K | 15K |
Selling & Marketing Expenses | n/a | -1.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 142.66M | 139.56M | 111.31M | 96.84M | 99.55M | 107.25M | 95.06M | 93.01M | 72.53M | 64.49M | 54.53M | 50.51M | 50.57M |
Income Tax Expense | 138K | 188K | 123K | 107K | 85K | 160K | 4.87M | 8K | -4.24M | 119K | -13K | -10K | -15K |
Shares Outstanding (Basic) | 181.61M | 174.6M | 157.5M | 157.05M | 156.65M | 156.37M | 152.3M | 148.3M | 147.98M | 147.3M | 144.02M | 127.48M | 127.23M |
Shares Outstanding (Diluted) | 181.61M | 174.6M | 157.5M | 157.05M | 156.65M | 156.37M | 152.3M | 148.3M | 147.98M | 147.3M | 144.02M | 127.48M | 127.23M |
EPS (Basic) | -0.73 | -0.76 | -0.61 | -0.63 | -0.67 | -0.59 | -0.69 | -0.61 | -0.43 | -0.4 | -0.43 | -0.42 | -0.4 |
EPS (Diluted) | -0.73 | -0.76 | -0.61 | -0.63 | -0.67 | -0.59 | -0.69 | -0.61 | -0.43 | -0.4 | -0.43 | -0.42 | -0.4 |
EBITDA | -141.12M | -138.06M | -92.14M | -95.44M | -98.23M | -93.35M | -95.06M | -91.11M | -71.12M | -63.4M | -54.53M | -50.51M | -50.57M |
EBIT | -140.93M | -129.82M | -93.59M | -96.79M | -97.76M | -86.7M | -98.65M | -93.01M | -68M | -58.94M | -62.05M | -53.23M | -50.97M |
Depreciation & Amortization | 1.54M | 1.5M | 1.45M | 1.35M | 1.32M | 1.29M | 1.27M | 1.22M | 1.12M | 1.64M | 980K | 601K | 63K |